The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.
Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.
The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.
The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.
The home IoT platform floated at the foot of its range to raise almost $103m, while Xiaomi will retain a 16.4% stake in the company.
The Astra Zeneca antibiotic development spin off has floated in an initial public offering in which Novo bought more than $16m in shares.